- Aditxt ( NASDAQ: ADTX ) said on Friday that it completed a toxicology study that indicated the safety of its immunotherapeutic technology drug ADI-100, to treat rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.
- ( ADTX ) stock surged 61% before the bell.
- The company said that the result will provide help when the company files an Investigational New Drug ( IND ) application with the regulatory agencies.
For further details see:
Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate